Both alirocumab and evolocumab, whichare PCSK9 inhibitors, have been approved by theFood and Drug Administration (FDA) for treatingpatients with familial hypercholesterolemia, statinintolerance or contraindication, and ASCVD. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.